Eicosapentaenoic acid enhances mesenchymal stromal cell effects in experimental allergic asthma

      Rationale: Asthma is an increasing global health issue with no effective therapeutic interventions to repair the chronic airway remodeling that occurs. Systemic administration of mesenchymal stromal cells (MSCs) mitigates lung inflammation in experimental allergic asthma; however, effects on reducing airway remodeling are limited. Metabolites derived from eicosapentaenoic acid (EPA) supplementation may stimulate MSCs and potentiate their anti-inflammatory and anti-fibrogenic properties. The aim of this study was To investigate whether pre-treatment with EPA potentiates MSC therapeutic properties in experimental allergic asthma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect